by The Acute Ischemic Stroke (AIS) market is estimated to be valued at US$ 8,517.0 Million in 2021 and is expected to exhibit a CAGR of 4.0% over the forecast period 2021-2028, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
The Acute Ischemic Stroke (AIS) market involves the diagnosis and treatment of stroke, specifically ischemic strokes caused by a blood clot blocking a blood vessel to the brain. AIS occurs when there is a sudden interruption of blood flow to the brain, leading to severe health consequences such as paralysis, speech problems, and even death. The market offers a range of diagnostic tools and treatment options including thrombolytic therapies, endovascular procedures, and surgical interventions. These products aid in the timely and effective management of stroke patients, reducing the risk of disability and improving survival rates.
Market Dynamics:
The market dynamics of the AIS market are driven by two key factors. Firstly, the increasing prevalence of stroke worldwide is a major driver for the market growth. The rising aging population, sedentary lifestyle, and increasing incidence of risk factors such as hypertension, diabetes, and smoking contribute to a higher incidence of stroke. As a result, there is a growing demand for advanced diagnostic and treatment solutions for stroke management.
Secondly, advancements in stroke treatment technologies and therapies provide significant growth opportunities for market players. Technological advancements such as the development of minimally invasive endovascular procedures, novel thrombolytic agents, and neuroprotective drugs have improved the outcomes for stroke patients. These advancements offer better efficacy, safety, and ease of use, driving the adoption of these products in clinical practice.
Segment Analysis:
The Acute Ischemic Stroke (AIS) market can be segmented based on the type of treatment. The dominating segment in this market is thrombolytic therapy. Thrombolytic therapy involves the administration of drugs such as tissue plasminogen activator (tPA) to dissolve the blood clot causing the stroke. This segment dominates the market due to its effectiveness in improving blood flow to the brain and minimizing damage caused by the stroke. The widespread adoption of thrombolytic therapy by healthcare professionals is driving the growth of this segment.
PEST Analysis:
Political: The political landscape plays a crucial role in the AIS market. Government regulations and policies regarding healthcare, drug approvals, and insurance coverage for stroke treatments can significantly impact the market dynamics.
Economic: The economic factors affecting the AIS market include healthcare expenditure, healthcare infrastructure, and reimbursement policies. The increasing healthcare expenditure and improving healthcare infrastructure in emerging economies are driving the growth of the AIS market.
Social: The social factors influencing the AIS market include the aging population, lifestyle choices, and awareness about stroke symptoms. The aging population is more prone to strokes, leading to a higher demand for AIS treatments.
Technological: Technological advancements in stroke diagnosis and treatment have revolutionized the AIS market. The development of innovative medical devices, imaging techniques, and telemedicine solutions has improved patient outcomes and expanded treatment options.
Key Takeaways:
The Global Acute Ischemic Stroke (AIS) Market Demand is expected to witness high growth, exhibiting a CAGR of 4.0% over the forecast period. This growth is driven by increasing awareness about stroke symptoms and the availability of effective treatment options.
In terms of regional analysis, North America is the fastest-growing and dominating region in the AIS market. The region has well-developed healthcare infrastructure, a large patient pool, and favorable reimbursement policies. The presence of key market players and ongoing research and development activities in this region further contribute to its dominance.
Key players operating in the AIS market include F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio, and Athersys Inc. These key players have extensive product portfolios, strong distribution networks, and focus on research and development to gain a competitive edge in the market.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
